Notably, this atherogenic risk-assessing value of AIP is also relevant to cognitive outcomes: studies have shown that elevated AIP levels correlate with a higher risk of cognitive impairment in adults around 60 years of age [9], aligning with the age profile of our CHARLS-based study population. The gene discussed is AIP; the disease is Cognitive impairment.